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Abstract
INTRODUCTION: The direct relationship between surgical radicality to
compensate biologic behavior and improvement of patient outcome at the time
of primary or interval cytoreduction remains unclear. OBJECTIVE: The aim
of this study was to evaluate the impact of disease extension and surgical
complexity on survival after complete macroscopic resection for stage IIIC-IV
ovarian cancer. MATERIALS AND METHODS: Medical records from seven
referral centers in France were reviewed to identify all patients who had
complete cytoreductive surgery for stage IIIC-IV epithelial ovarian, fallopian, or
primary peritoneal cancer. All patients had at least six cycles of carboplatin and
paclitaxel combination therapy. RESULTS: From the 374 consecutive patients
with complete cytoreduction who were included in this study, stage, grade,
upper abdominal disease, surgical complexity, and carcinomatosis extent were
significantly associated with disease-free survival (DFS) at univariate analysis.
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ABSTRACT
Introduction. The direct relationship between surgical
radicality to compensate biologic behavior and improve-
ment of patient outcome at the time of primary or interval
cytoreduction remains unclear.
Objective. The aim of this study was to evaluate the
impact of disease extension and surgical complexity on
survival after complete macroscopic resection for stage
IIIC–IV ovarian cancer.
Materials and Methods. Medical records from seven
referral centers in France were reviewed to identify all
patients who had complete cytoreductive surgery for stage
IIIC–IV epithelial ovarian, fallopian, or primary peritoneal
cancer. All patients had at least six cycles of carboplatin
and paclitaxel combination therapy.
Results. From the 374 consecutive patients with complete
cytoreduction who were included in this study, stage,
grade, upper abdominal disease, surgical complexity, and
carcinomatosis extent were significantly associated with
disease-free survival (DFS) at univariate analysis. Stage IV
and the need for ultra-radical procedures were significantly
associated with lower overall survival (OS). On multi-
variate analysis, radical surgery, including more than two
visceral resections, was significantly associated with
decreased DFS and OS.
Conclusions. Patients who need complex surgical proce-
dures involving two or more visceral resections in order to
achieve successful complete cytoreduction have worse
outcome than patients with less extensive procedures. The
negative impact of surgical complexity was not significant
in patients who underwent upfront procedures. Tumor
volume and extension were associated with decreased DFS
in patients undergoing a primary surgical approach. This
adds to the evidence that, even though complete cytore-
duction is currently the objective of surgery, tumor load
remains an independent poor prognostic factor and proba-
bly reflects a more aggressive behavior.
Complete removal of all macroscopic tumor is the single
most important prognostic factor for long-term survival in
patients with advanced ovarian cancer.1,2 Peroperative
care, infrastructure, and resectability criteria have evolved.
Surgical skills, especially the approach to advanced ovarian
cancer involving the upper abdomen, have improved the
rate of optimal cytoreduction,3 and the addition of these
procedures has increased the rate of complete cytoreduc-
tion surgery. On the other hand, the outcome of surgery
also depends on the patient’s ability to tolerate an extensive
surgical approach.4 Morbidity and mortality associated
with these procedures are strongly related to the perfor-
mance of extended abdominal visceral resections.5
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Literature evidence shows that completeness of cytore-
duction (CC) has a more significant influence on survival
than the extent of peritoneal disease. Memorial Sloan
Kettering Cancer Center (MSKCC) experience demon-
strated that complete cytoreduction decreases the risk of
recurrence and death irrespective of the initial presence and
volume of upper abdominal tumor burden present at the
beginning of surgery.4 Most authors have focused on the
importance of complete cytoreduction and the effect of
surgical outcome criteria on survival, especially since
upper abdominal procedures have been incorporated in
order to ensure no macroscopic residual disease is present.
The primary aim of this study was to evaluate the impact
of disease extension and surgical complexity on survival in
stage IIIC–IV patients with complete macroscopic resec-
tion after primary or interval debulking surgery for
advanced ovarian cancer.
MATERIALS AND METHODS
A search of the institutional patient database was per-
formed to retrospectively identify all patients who
underwent cytoreductive surgery (CRS) for stage IIIC–IV
epithelial ovarian, fallopian, or primary peritoneal cancer
between January 2003 and December 2007 in seven insti-
tutions in France that were recognized as referral centers in
the treatment of ovarian cancer. In all cases, preoperative
imaging included a computed tomography (CT) of the
chest, abdomen, and pelvis, and, in selected cases, a
positron emission tomography (PET) CT.
All operations were performed by a gynecologist
oncologist under the supervision of a senior gynecologist
oncologist. All patients underwent complete cytoreduction
surgery to no macroscopic residue, and had at least six
cycles of carboplatin and paclitaxel combination therapy.
Adjuvant chemotherapy was administered within 2 months
of surgery, when feasible, at the discretion of the treating
oncologist. No anti-angiogenic agents were used in any
patient included in the current study. Patients in whom
surgical procedures were not detailed enough in the oper-
ative records, and patients with non-epithelial histology or
borderline tumors were excluded from the study. The study
was approved by the Institutional Review Board from the
Institut Claudius Regaud (ICR).
Medical records were reviewed and patient demographic
data, with particular emphasis on operative records to
detail the extent and distribution of disease spread, surgical
procedures, chemotherapy treatment, and follow-up data,
were included. Extent and distribution of the 13 abdomi-
nopelvic regions and surgical outcome was evaluated using
the peritoneal cancer index (PCI) and CC score.6 Surgical
complexity was defined according to visceral resections,
and supraradical procedures were defined as cytoreduction
surgeries requiring at least two visceral resections. Surgical
and pathology variables were analyzed to investigate their
potential as biological markers of poor outcome in patients
who underwent a complete surgical procedure.
Statistical Methodology
Data were summarized using frequency and percentage
for categorical variables, and median and range for con-
tinuous variables. All reported p values were two-sided.
For all statistical tests, differences were considered sig-
nificant at the 5 % level, and statistical analyses were
performed using STATA 12.0 software (StataCorp LP,
College Station, TX, USA).
RESULTS
A total of 374 consecutive patients with complete CRS
type CC0 were included in the study. Median age was
58 years at diagnosis (24–85 years), and 325 patients
(86.9 %) were stage IIIc and 49 (13.1 %) were stage IV.
Patient and tumor characteristics are shown in Table 1.
Overall, 125 patients (33.4 %) underwent primary CRS,
194 patients (51.9 %) underwent interval cytoreduction
surgery after three to four cycles of neoadjuvant
chemotherapy, and 55 patients (14.7 %) underwent surgery
after six cycles of neoadjuvant chemotherapy. Twenty-one
patients (5.7 %) had a hyperthermic intraperitoneal
chemotherapy (HIPEC) procedure, and 26 patients (7.2 %)
had intraperitoneal chemotherapy. Median PCI was 8
(range 0–31) for all patients included in the study, 11
(range 3–31) for patients who underwent upfront surgery, 6
(0–31) for patients who underwent interval surgery after
three to four cycles of chemotherapy, and 7 (0–17) for
patients who underwent surgery after six cycles of
chemotherapy. Para-aortic lymphadenectomy was per-
formed in 310 patients (83.6 %), while 185 patients
(49.5 %) required at least one visceral resection. Large
bowel resection was required in 40 % of patients, small
bowel resection in 10 % of patients, and multiple bowel
resections in 12 % of patients. Upper abdominal proce-
dures consisted of right diaphragmatic procedures in
42.5 % of patients, left diaphragmatic procedures in
14.2 % of patients, liver resections in 4 % of patients,
splenectomies in 10 % of patients, and procedures
including peritoneal stripping of the porta hepatis and/or
celiac lymph node resection in 2.4 % of patients (Fig. 1).
After a median follow-up of 47.7 months [95 % confi-
dence interval (CI) 44.2–52.4], median progression-free
survival (PFS) was 19.5 months (95 % CI 18–21.8), with
an estimated disease-free survival (DFS) of 77.9 % (95 %
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CI 73.3–81.8) at 12 months, 40 % (95 % CI 34.9–45) at
24 months, 26.7 % (95 % CI 22.1–31) at 36 months, and
22.2 % (95 % CI 17.9–26.9) at 48 months. Median DFS
was 24.2 months in patients undergoing primary surgery,
19.1 months in patients undergoing interval procedures,
and 16.9 months in patients undergoing surgery after six
cycles of chemotherapy. Median overall survival (OS) was
not reached. Estimated OS was 96.7 % (95 % CI 94.3–
98.1) at 12 months, 86.2 % (95 % CI 82.1–89.4) at
24 months, 73.2 % (95 % CI 68–77.7) at 36 months, and
61.1 % (95 % CI 55–66.5) at 48 months.
On univariate analysis, stage, grade, upper abdominal
disease, surgical complexity, neoadjuvant chemotherapy,
and PCI were significantly associated with DFS, while
stage and surgical complexity were significantly associated
with OS. PCI remained a prognostic factor with a trend
towards decreased OS (see Table 2). On multivariate
analysis, decreased PFS was found in patients who
underwent interval cytoreduction and patients who
required two or more visceral resections. Surgical com-
plexity was also significantly associated with decreased
OS.
In the subgroup of patients who underwent upfront
surgery, stage, grade, and carcinomatosis extent were sig-
nificantly associated with decreased PFS in univariate
analysis. Grade was the only factor significantly associated
with decreased OS, and surgical complexity was not sig-
nificantly associated with decreased PFS (p = 0.08). In
multivariate analyses, disease extension measured by the
PCI was the only significant factor associated with
decreased PFS, with a non-significant trend to decreased
OS (p = 0.07). Resistance to platinum after complete
cytoreduction was significantly associated with high grade,
papillary serous histology, upper abdominal disease, higher
tumor load, and surgical complexity. No specific locations
were associated with decreased survival, with the exception
of bowel spread. A significant association was noted
between increased progression during the 6 months that
followed the end of chemotherapy and bowel disease
requiring at least one bowel resection. There was also a
non-significant association between patients who required
celiac lymph node resection and resistance to platinum
(p = 0.09).
DISCUSSION
As the absence of visible tumor residue is the most
important prognostic factor for long-term survival,1 it is
hypothesized that this effect is driven by the removal of
chemoresistant clones and poorly vascularized tumor; a
higher growth fraction in better perfused, small residual
tumors increases chemosensitivity and improves host
immunocompetence by resection of bulky tumor.7 Most of
the previous reports focus on the survival effect of residual
disease and timing of surgical effort in patients with
extended disease requiring complex procedures; however,
the effect of disease burden as well as surgical aggressivity
have been poorly investigated.
The extent of disease as a marker of biological aggres-
siveness in patients with no residual tumor after surgery
remains under discussion. Eisenkop et al. demonstrated
that complete surgical cytoreduction has a more significant
independent influence on survival than total extent of intra-
abdominal tumor burden.8 They also found that there are
no specific intra-abdominal tumor locations or surgical
procedures that correlate with tumor-inherent biological
aggressiveness.8 In our series, two or more bowel resec-
tions were associated with early recurrent disease. These
TABLE 1 Clinical characteristics
N (%)
Stage
IIIC 325 (86.9)
IV 49 (13.1)
Gradea
1 27 (9.2)
2 89 (30.3)
3 178 (60.5)
Histologic type
Serous 274 (73.2)
Clear cell 10 (2.7)
Mucinous 9 (2.4)
Endometrioid 36 (9.6)
Otherb 45 (12)
Surgical procedures
Hysterectomy 348 (93)
BSO 358 (96)
Omentectomy 367 (98.1)
Bowel resection
Small bowel resection 36 (9.7)
Large bowel resection 149 (39.9)
Multiple bowel resections 45 (12.1)
Appendectomy 250 (67)
Lymphadenectomy
Pelvic 319 (85.5)
Aortic 310 (83.6)
Peritonectomy
Right upper quadrant 159 (42.5)
Left upper quadrant 53 (14.2)
Median preoperative CA 125 800 (18–90,000)
Median ascites, ml (range) 50 (0–8000)
BSO bilateral salpingo-oophorectomy
a Unknown for 80 patients
b Undifferentiated, transitional, mixed
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patients presented with higher tumor burden, with a median
PCI of 16 (2–31), compared with a median PCI of 7 (0–31)
(p\ 0.001) in patients with no bowel resection. No sig-
nificative difference was observed between the number of
bowel resections and time of surgery, with 20 patients
(44.4 %) opting for an upfront surgical approach, 21
patients (46.7 %) opting for interval surgery, and 4 patients
(8.9 %) opting for surgery after six cycles of chemother-
apy. This may overestimate the prognostic impact of bowel
resection as patients undergoing interval procedures
requiring multiple bowel resections probably had higher
associated chemotherapy resistance. Median survival in
patients with multiple bowel resections was of only
15 months. Jaeger et al. reported that bowel involvement in
epithelial ovarian cancer had a bad prognosis and that
survival could not substantially be improved by bowel
resection, independently from the residual disease
achieved.9 Other studies have shown that multiple bowel
resections are associated with poor prognostic outcome due
to the increased risk of postoperative morbidity. Anasto-
motic leaks can have a negative impact on hospital length,
delay in starting chemotherapy, and 90-day mortality and
OS.10 In our series, data were unavailable as postoperative
morbidity and time to chemotherapy were potentially
increased in patients with multiple bowel resections;
however, higher postoperative 90-day mortality was not
observed in these patients. Literature data addressing the
question of the impact of bowel resection on outcome after
cytoreduction remain unclear because of the lack of uni-
form data showing improved survival.11 Several series also
support survival benefit in patients with extensive upper
abdominal disease requiring radical cytoreductive proce-
dures when compared with patients completely
cytoreduced by less aggressive surgery.12–14 MSKCC
experience demonstrated that complete cytoreduction
decreases the risk of recurrence and death irrespective of
the initial presence and volume of upper abdominal tumor
burden present at the beginning of surgery.4 The benefit of
complete surgery remains even after occurrence of recur-
rent disease.2
Hamilton et al. have recently addressed this question by
evaluating 417 advanced ovarian cancer patients with no
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FIG. 1 Disease-free and overall survival. a DFS in patients with
primary, interval surgery after three to four cycles, and surgery after
six cycles of neoadjuvant chemotherapy; b DFS according to surgical
complexity; c OS in patients with stage IIIC and IV; d OS according
to surgical complexity. DFS disease-free survival, OS overall survival
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residual tumor after CRS. Patients with upper abdominal
disease and no residual tumor after surgery had a poorer
prognosis than similarly staged patients whose initial dis-
ease burden did not involve the upper abdomen.15 Hoskins
et al. [Gynecologic Oncology Group (GOG) 52] found
similar results, and concluded that initial extra-pelvic dis-
ease remained a significant predictor of decreased
survival.16 The MSKCC series including 526 patients
found decreased PFS and OS with increasing initial tumor
burden, suggesting more aggressive biological disease or
disease for a longer period of time. However, significant
survival benefit was still observed in high-risk groups after
CRS.4
In the present study, tumor extension, as measured by
the PCI, was the only significant prognostic factor associ-
ated with decreased DFS in patients who underwent
complete upfront surgery. Other reports have identified
clinical markers of decreased survival, even when complete
TABLE 2 Prognostic factors after complete cytoreduction
Univariate analysis HR (95 % CI) DFS p value (log-rank) HR (95 % CI) OS p value (log-rank)
Stage
IIIC 1.00 0.002 1.00 0.010
IV 1.65 (1.19–2.30) 1.76 (1.13–2.75)
Upper abdominal procedure
0 1.0 0.0161 1.00 0.18
0–25 1.39 (1.05–1.84) 1.31 (0.87–1.96)
[25 1.52 (1.08–2.12) 1.52 (0.94–2.46)
Surgical complexity
Standard staging 1.00 0.0001 1.00 0.018
One visceral resection 1.65 (1.23–2.21) 1.38 (0.90–2.14)
Two or more visceral resections 1.9 (1.44–2.51) 1.75 (1.18–2.60)
PCI scorea 1.03 (1.01–1.06) 0.001 1.03 (0.99–1.06) 0.068
Upfront versus interval surgery
Upfront surgery 1.00 0.0226 1.00 0.155
Interval surgery (three to four cycles) 1.41 (1.07–1.84) 1.47 (0.99–2.17)
Surgery after six cycles 1.52 (1.05–2.20) 1.21 (0.68–2.17)
Multivariate analysis HR (95 % CI) DFS p value (wald) HR (95 % CI) OS p value (wald)
Stage
IIIC 1.00 0.092 1.00 0.014
IV 1.43 (0.94–2.16) 1.76 (1.12–2.76)
Upperabdominal procedureb
0 1.00 0.806 NA NA
0–25 0.94 (0.55–1.55) 0.740
[25 0.89 (0.44–1.69)
Surgical complexity
Standard staging 1.00 1.00
One visceral resection 1.71 (0.96–3.02) 0.062 1.46 (0.94–2.26) 0.089
Two or more visceral resections 2.01 (1.09–3.71) 0.024 1.70 (1.15–2.54) 0.008
PCI scorea 1.01 (0.97–1.05) 0.748
Upfront versus interval surgery
Upfront surgery 1.00 0.248 NA NA
Interval surgery (three to four cycles) 1.26 (0.85–1.85) 0.253
Surgery after six cycles 1.51 (0.75–3.04)
Bold values indicate the significant if p\ 0.05
HR hazard ratio, CI confidence interval, DFS disease-free survival, OS overall survival, PCI Peritoneal Cancer Index, NA not applicable
a Treated as a continuous variable
b Upper abdominal procedure: defines volume of upper abdominal disease, in mm
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CRS is achieved. In a previous study, positive coeliac
lymph node involvement in patients with peritoneal car-
cinomatosis defined a less favorable patient subgroup
which was associated with poor oncologic outcome and
resistance to platinum-based chemotherapy.17 The Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) 55971 randomized trial demonstrated that the
combined analyses of tumor size and clinical stage were
significantly associated with treatment benefit and 5-year
survival.18 Treatment strategy based on both markers was
proposed for stage IIIc and IV ovarian cancer by selecting
stage IIIc patients with the largest metastatic tumor
B45 mm to primary surgery, stage IIIc patients with the
largest metastatic tumor[45 mm or stage IV patients with
the largest metastatic tumor B45 mm to either surgery or
neoadjuvant chemotherapy, and patients with clinical stage
IV and the largest metastatic tumor [45 mm to neoadju-
vant chemotherapy.18 The authors stated that this strategy
could improve 5-year survival in more than 6 % in the
corresponding patient population. Marginally better sur-
vival has also been found in patients randomly assigned to
primary debulking with metastases smaller than 5 cm.18 In
the present study, size of upper abdominal disease was also
related to PFS in univariate analysis.
Surgical practice has demonstrated that most disease
locations are amenable to cytoreduction with improved
survival and reasonable morbidity.19 In our series, surgical
complexity was an independent marker of OS when com-
plete surgery was achieved, which may be explained by the
selection of patients with poor response to chemotherapy at
the time of interval surgery. This suggests that surgical
effort is not enough to compensate tumor biology; how-
ever, negative prognostic impact of complex procedures
was not seen in patients undergoing upfront surgery.
Horowitz et al. reported that patients with the highest
disease burden defined by upper abdominal disease had
significantly shorter DFS (18.3 vs. 33.2 months) and OS
(50.1 vs. 82.8 months) compared with those with moderate
or low disease burden after complete cytoreduction.20 In
the present series, DFS after complete upfront surgery was
24.1 months, inferior to that reported in some studies.21,22
This may be explained by the population-based study
including a high proportion of patients with upper
abdominal disease referred from other institutions. DFS
after complete interval surgery at three cycles was
19.1 months, and 16.9 months after six cycles of
chemotherapy. Horowitz et al. reported that only 199
patients from the 1636 patients with high disease burden
who were included in the study (12 %) were completely
cytoreduced. In our series, 64 % of patients with high
disease burden or upper abominal disease were completely
cytoreduced. The rate of upper abdominal procedures
required in our study was similar to previous reports. In this
series, the rate of diaphragm strippings, splenectomies,
hepatic resections, and porta-hepatis procedures were
similar to those reported by the two largest series of upper
abdominal surgery in which 13–35 % of diaphragm pro-
cedures, 4–12 % of splenectomies, 0.5–4 % of
pancreatectomies, 4–6 % of hepatic resections, and 0.2–
5 % of porta-hepatis procedures are described.23,24 As in
previous series, the right diaphragmatic procedure was the
most common upper abdominal procedure.
Primary cytoreduction with complete resection followed
by adjuvant chemotherapy is the mainstay of advanced
ovarian cancer treatment. Even when complete resection
can be achieved in patients with good performance status,
other criteria should be incorporated in the clinical signa-
ture to predict a patient’s outcome. It is important to
integrate extension of disease, surgical complexity,
including number of visceral resections required, and
associated morbidity and mortality in order to improve
treatment strategy.
Limitations of this study include its retrospective nature,
and the absence of morbidity and mortality data of surgical
procedures. Sample size was small and was also limited by
heterogeneous treatment strategies, including patients who
underwent upfront surgery, interval debulking, HIPEC, and
postoperative intraperitoneal chemotherapy. There is also a
potential bias in the proportion of patients with platinum
resistance in the present study as refractory patients who
did not undergo debulking surgery were not included in the
analysis. In this series, the rate of patients who received
neoadjuvant chemotherapy is high, which can be explained
by the high proportion of patients referred to our institu-
tions after external evaluation and once neoadjuvant
chemotherapy had been previously started.
CONCLUSIONS
Stage IIIC–IV ovarian cancer patients who require
successful complete cytoreduction by complex surgical
procedures had worse outcome than patients requiring
standard procedures. The negative impact of surgical
complexity was not significant in patients who underwent
upfront procedures. Extensive disease requiring two or
more visceral resections to obtain complete cytoreduction
at the time of interval debulking was an independent poor
prognostic factor and probably reflects a more aggressive
behavior. Standard platinum- and taxane-based adjuvant
chemotherapy do not seem to be adapted to this subgroup
of patients, and specific adjuvant strategy should be
considered. Tumor volume and extension was associated
with decreased DFS in patients who underwent upfront
surgery.
A. Martinez et al.
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